Exploratory study of immunologic factors in re-biopsy specimen, peritumoral bronchoalveolar lavage fluid (BALF), and the peripheral blood for predicting response to the third generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Osimertinib on non-small cell lung cancer patients with resistance to the first generation or the second generation EGFR-TKI
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000023853
- Lead Sponsor
- Osaka University, Graduate school of Medicine, Respiratory medicine, Allergy and Rheumatic Disease
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
1 Drug induced pneumonitis or lung fibrosis 2 Past interstitial pneumonitis 3 Synchronous or metachronous cancer 4 Inappropriate patient
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The relationship between response to Osimertinib and a lymphocyte profile in serum, plasma or BALF, and the gene profile in tumor specimen
- Secondary Outcome Measures
Name Time Method The relationship between response to anti-cancer agent except Osimertinib and a lymphocyte profile in serum, plasma or BALF, and the gene profile in tumor specimen